NasdaqCM - Nasdaq Real Time Price USD

Autonomix Medical, Inc. (AMIX)

1.9500
+0.0500
+(2.63%)
At close: May 16 at 4:00:02 PM EDT
1.9499
-0.00
(-0.01%)
After hours: May 16 at 6:05:23 PM EDT
Loading Chart for AMIX
  • Previous Close 1.9000
  • Open 1.8100
  • Bid 1.8700 x 100
  • Ask 1.9900 x 100
  • Day's Range 1.8100 - 1.9500
  • 52 Week Range 1.5200 - 56.0000
  • Volume 175,635
  • Avg. Volume 130,919
  • Market Cap (intraday) 4.803M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -17.2300
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.50

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. It has an agreement with NoiseFigure Research, Inc. to develop next generation of its proprietary microchip. Autonomix Medical, Inc. was incorporated in 2014 and is based in The Woodlands, Texas.

autonomix.com

5

Full Time Employees

March 31

Fiscal Year Ends

Recent News: AMIX

View More

Performance Overview: AMIX

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AMIX
48.14%
S&P 500 (^GSPC)
1.30%

1-Year Return

AMIX
96.13%
S&P 500 (^GSPC)
12.48%

3-Year Return

AMIX
98.72%
S&P 500 (^GSPC)
48.66%

5-Year Return

AMIX
98.72%
S&P 500 (^GSPC)
108.07%

Compare To: AMIX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AMIX

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    4.80M

  • Enterprise Value

    -5.89M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.49

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -97.67%

  • Return on Equity (ttm)

    -662.79%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -13.63M

  • Diluted EPS (ttm)

    -17.2300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.82M

  • Total Debt/Equity (mrq)

    11.66%

  • Levered Free Cash Flow (ttm)

    -4.69M

Research Analysis: AMIX

View More

Company Insights: AMIX

Research Reports: AMIX

View More

People Also Watch